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Background: The objective of this study was to assess the potential clinical value of the concentration of soluble 
salivary E-cadherin (sE-cadherin) compared with the clinical value of the presence of membranous E-cadherin 
(mE-cadherin) in oral squamous cell carcinoma tumor tissues. 
Material and Methods: Data regarding patient demographics, clinical stage, saliva and tumor tissue samples were 
collected. The saliva was analyzed for sE-cadherin protein levels and was compared to the mE-cadherin immu-
nohistochemical expression levels in tumor tissues, which were assessed via the HercepTest® method. Patients 
without cancer were included in the study as a control group for comparisons of the sE-cadherin levels. 
Results: sE-cadherin levels in the saliva of patients without cancer were lower than those in patients with cancer, 
and the difference was statistically significant (p=0.031). Low mE-cadherin expression was statistically signifi-
cantly associated with lymph node positivity (p=0.015) and advanced clinical stage (p=0.001). The inverse rela-
tionship between mE-cadherin and sE-cadherin was significant in terms of lymph node positivity (p=0.014) and 
advanced clinical stage (p=0.037). 
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Introduction
Oral epithelial cells possess unique morphological char-
acteristics, including extensive inter-cellular junctional 
complexes and stable cell-cell and cell-matrix adhesions 
(1). The decrease in the levels of cell-cell adhesion mol-
ecules is central to the development of aggressive carci-
nomas because the absence of these molecules enables 
the cancer cell to break free from the primary tumor 
and migrate to local and distant sites within the body to 
form new tumors (2).
E-cadherin belongs to the cadherin family of proteins, 
which was first described in connection with tissue 
specificity since these proteins were found in epithelial 
tissues (3). E-cadherin is a 120-kDa transmembrane 
glycoprotein encoded by the CDH1 gene located on 
chromosome 16q22.1a. It enables junctional adherence 
via the binding of the extracellular domains of E-cad-
herin molecules between adjacent cells and the bind-
ing of intra-cytoplasmic domains with catenins, which 
are cytoplasmic proteins that connect E-cadherin to the 
cytoskeleton (4,5). This allows the participation of E-
cadherin in the transduction of signals that control sev-
eral cellular events, including polarity, differentiation, 
growth and cell migration (6).
Although reduced expression of E-cadherin was once 
considered necessary for metastatic dissemination, sev-
eral reports have documented invasive and aggressive 
tumors that nonetheless maintain E-cadherin expres-
sion (7-10).
It is now known that not only does its reduced expres-
sion play a role in the transition to a malignant pheno-
type and in cancer progression but that the proteolysis 
of E-cadherin by several proteases converts the mature 
120-kDa E-cadherin to an extracellular N-terminal 80-
kDa fragment termed soluble E-cadherin (sE-cadherin), 
which serves as a paracrine/autocrine signaling mole-
cule in cancer (11). 
It has been reported that the serum levels of sE-cad-
herin are higher in oncological patients than in healthy 
subjects (12-14). It is possible that similar results could 
be observed in saliva, which is a popular fluid for use 
in oral squamous cell carcinoma (OSCC) (1) research 
because saliva is present in a certain composition and 
responds to events in the oral cavity (15).
The goal of our research was to determine, for the 
first time, the concentration of salivary sE-cadherin in 
OSCC, to assess the membrane expression of E-cadher-
in, to correlate this expression with disease characteris-
tics and to determine the association between sE-cad-
herin and membranous E-cadherin (mE-cadherin).
Material and Methods
-Patients 
Individuals diagnosed with OSCC who were patients at 
the Jalisco Institute of Oncology between January 2013 
and February 2015 were enrolled in the study. In all, 26 
patients were enrolled (12 male and 14 female subjects, 
aged 61.9 ± 16.7 years). The reason for the greater num-
ber of female patients was simply because they volun-
teered in greater numbers. 
In addition, samples from 10 individuals without OSCC 
who visited the clinic for teeth extraction due to orth-
odontic or prosthetic indications were included (4 male 
and 6 female patients, aged 57.3 ± 8.5 years) and were 
treated at the Civil Hospital “Dr. Juan I Menchaca”.
The stage of the disease was evaluated in the Surgical 
Head and Neck Oncology Department, and each tumor 
was analyzed clinically and by computerized tomogra-
phy. The disease stages were then determined accord-
ing to the TNM system (16).
Due to the finding that the diameter of the tumor and the 
invasion into lymphatic nodes are regarded as important 
clinical markers involved in prognosis, the lymphatic 
nodes were considered positive if patients presented 
metastasis in one or more lymphatic nodes. T stage and 
total TNM scores were redistributed in accordance with 
the NCI guidelines (17), and each case was determined 
to be early- or advanced-stage disease, as shown in Ta-
ble 1. According to this system, advanced T stage refers 
to tumors that are larger than 4 cm, whereas advanced 
TNM stage also incorporates tumors of a smaller size 
that are accompanied by positive lymphatic nodes with 
or without distant metastasis.
Confirmation of the diagnosis and the tumor grade (dif-
ferentiation) was determined according to the WHO cri-
teria (18). Both procedures were performed by an oral 
pathologist. Informed consent from each patient was 
included in the study protocol, which was submitted to 
and approved by the ethics committee of the institute. 
The authors have read the Declaration of Helsinki and 
have followed its guidelines in this investigation.
-Selection Criteria
Patients diagnosed with OSCC, who did not receive 
chemotherapy or radiotherapy, or any other oncologi-
cal treatment including surgery, were enrolled in this 
study. Individuals without OSCC but who experienced 
Conclusions: The results suggest that sE-cadherin levels are significantly increased in patients with oral cancer and 
that its low expression within the membrane as well as the progression of the disease appear to be inversely associ-
ated with levels of sE-cadherin in the saliva.
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epithelial autoimmune or inflammatory disease, those 
who presented isolated ulcerous disorders, e.g., trau-
matic disorders, or any other kind of lesion in the oral 
mucosa, and those with any oncological history were 
excluded from the study.
-Samples
Unstimulated saliva was collected between 9 and 11 
AM before any surgical procedure was performed and 
was preserved according to a previously described pro-
tocol (19). Saliva was not collected from patients who 
had consumed alcohol, smoked tobacco or performed 
oral hygiene procedures up to 30 minutes before sample 
collection or from those who presented bleeding of the 
gums or of any other location within the oral cavity. 
Biopsy tissue samples were collected by an oncologi-
cal surgeon and were divided into two groups, as fol-
lows: one to be sent to the hospital for diagnosis, and 
the other (measuring 5 mm to 1 cm) to be included in 
experimental procedures. The tissue was immediately 
fixed in 10% formaldehyde for a minimum of 24 hours 
and no longer than 48 hours and was later paraffin-em-
bedded in the pathology laboratory of the Microbiology 
and Pathology Department; paraffin blocks were then 
sectioned for hematoxylin and eosin staining to confirm 
the diagnosis. 
-Enzyme-linked Immunosorbent Assay (ELISA)
The concentration of sE-cadherin was measured in the 
saliva of 24 OSCC patients. Saliva samples from two 
patients could not be collected or were insufficient for 
detection. It was also difficult to obtain adequate saliva 
for the laboratory procedures. This was because patients 
with tumors in the oral cavity generally experience lim-
ited mobility or paralysis or due to the size of the tumor 
and because the saliva usually contains blood from tu-
mor ulceration or is heavily contaminated because of 
oral hygiene (both are exclusion criteria according to 
the protocol).
We used the commercially available Quantikine® 
ELISA kit (R&D Systems, Minneapolis, MN, USA) ac-
cording to the manufacturer’s instructions. Briefly, the 
saliva sample was diluted, pipetted into the wells of the 
titer plates and incubated with detection antibodies at 
room temperature for 1 to 2 hours. After incubation, 
the solution was aspirated, and the wells were washed 
4 times. The substrate was added to each well for 20 
minutes at room temperature followed by the addition 
of stop solution. Optical density was measured in an 
ELISA reader (Bio-hazard model Powean WH4101). All 
tests were performed in triplicate, and the concentration 
was calculated from a validated standard curve using a 
simple linear regression model. Data regarding the total 
concentration of proteins were unnecessary since the kit 
we utilized did not require this value; this kit is spe-
cifically designed for the quantification of human sE-
cadherin and for the determination of its concentration 
in cell culture supernatants, serum, plasma, urine, and 
saliva, and therefore, the data are expressed as nano-
grams (ng) of E-cadherin per ml of saliva.
-Immunohistochemistry (IH)
Tissue samples from 26 cases were processed and eval-
uated. From the tissue blocks, 3-μm-thick sections were 
cut, placed on poly-L-lysine-coated slides, deparaf-
finized in a 60°C oven for 30 minutes and incubated in 
xylol for 5 minutes. The sections were then rehydrated 
in decreasing alcohol concentrations (absolute, 90, 70, 
and 50%) and washed in distilled water. To retrieve the 
epitopes, the tissue sections were heated in 10 mM so-
dium citrate solution at pH 9 in a microwave oven at a 
maximum power of 750 W for two cycles of 5 minutes 
each. The sections were then cooled to room tempera-
ture and washed with distilled water. Endogenous per-
oxidase was blocked with 0.9% hydrogen peroxide, and 
the samples were again washed with distilled water and 
phosphate-buffered saline solution (PBS, pH 7.4). The 
sections were incubated for 30 minutes with a prima-
ry antibody against E-cadherin (Clone NCH-38, 1:50, 
Dako Corp., Carpinteria, CA, USA); following this, the 
sections were incubated with a biotinylated anti-mouse/
anti-rabbit secondary antibody and streptavidin/per-
oxidase complex (LSA-B+ labeled streptavidin-biotin, 
Dako Corp.) for 30 minutes each. The reaction products 
were then detected with 3,3′-diaminobenzidine-H2O2 
(Dako Corp.). 
Negative and positive controls were obtained from par-
affin blocks containing samples of healthy mucosa and 
fibroma that were collected using a 5-mm punch and 
placed on the slides along with the samples. The slides 
were analyzed by an oral pathologist, and the cells were 
counted as previously described for the HercepTest® 
(DAKO, Carpinteria, CA, USA) for breast cancer (20). 
In this test, the staining intensity on the membrane and 
the percentage of stained cells are scored from 0 to 3+ 
as follows: 0, negative: no staining is observed or mem-
brane staining is observed in <10% of the tumor cells; 
1+, negative: faint/barely perceptible membrane stain-
ing is detected in >10% of tumor cells; 2+, weakly posi-
tive: weak to moderate complete membrane staining 
is visualized in >10% of tumor cells; and 3+, positive: 
strong and complete membrane staining is visualized in 
>10% of tumor cells. For statistical analyses, the scores 
were stratified into low (0 and 1+) and high (2+ and 3+) 
expression groups. The term mE-cadherin was created 
by associating this protein’s form of expression to its 
corresponding membrane region based on the presence 
of E-cadherin.
-Statistical Analysis
The sample size of cases included in this study was in 
agreement with a previous study in which sE-Cadherin 
was analyzed in head and neck cancer (21).
The size of the control groups was established by the 
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hospital’s internal policy and was adopted for success-
ful protocol authorization.
Data were captured and analyzed using descriptive and 
inferential non-parametric statistics (SPSS version 20). 
The sE-cadherin protein concentrations are expressed 
as median values because the Mann-Whitney U and 
Kruskal-Wallis tests for quantitative variables are com-
monly regarded as tests with which to determine medi-
ans within the population. Fisher’s Exact Test was used 
for qualitative variables because the number of samples 
for some of the analyses was less than or equal to 5. A p 
value <0.05 was considered statistically significant with 
a confidence interval (C.I.) of 95%. 
Results
In all, 26 patients with OSCC were included in this 
study. The TNM and clinical stages of the patients are 
shown in Table 1. 
The area where OSCC was most frequently found was 
the tongue (42.3%), followed by the alveolar mucosa 
(19.2%) and palate (19.2%). T1 and N0 were the stages 
most frequently reported among patients (46.1% and 
42.3%, respectively), but a high percentage of patients 
in advanced clinical stages (42.3%) was also detected. 
None of the patients were determined to have distant 
metastasis (M0).
The histopathological assessment of tumor tissues es-
tablished that 21 tumors (80.8%) were considered well-
differentiated, 4 (15.4%) were considered moderately 
differentiated, and finally, only one case (3.8%) was 
considered poorly differentiated. 
-sE-cadherin levels 
The median sE-cadherin level in the saliva of patients 
without cancer (median 3.64 ng/ml, minimum 1.32 ng/
ml and maximum 5.03 ng/ml) was lower than that in 
the saliva of cancer patients (median 5.07 ng/ml, mini-
mum 1.48 ng/ml and maximum 13.91 ng/ml), and the 
difference was statistically significant (p=0.031) (Fig. 
1A). The range in the levels of sE-cadherin was broad. 
However, we must note that the maximum levels of sE-
cadherin in controls did not exceed the median among 
the OSCC samples.
The difference in the levels of sE-cadherin was not sta-
tistically significant among cases that varied with re-
spect to T stage (p=0.159), N stage (p=0.120), clinical 
stage (p=0.857), or tumor grade (p=0.273). We also did 
not observe a marked tendency toward any particular 
stage. M stage was not considered in this analysis since 
we did not evaluate a comparative group.
-mE-cadherin expression 
The frequency of mE-cadherin expression in tumor tissues 
according to the HercepTest® was as follows: 23.0%=0, 
27.0%=1+, 30.7%=+2, and 19.2%=+3 (Fig. 1B).
A representative microscopic image of each HercepT-
est® score in stratified OSCC samples is shown in Fig-
ure 1C and D.
?
Variable  No. % 
     
Localization       
                               Tongue  11 42.3 
                                Palate  5 19.2 
                                Alveolar   5 19.2 
                                Lip  3 11.6 
                                Retromolar   2 7.7 
Tumor Size   
T1 12Early tumor   46.1 
T2 5 19.2 
 Advanced tumor T3 3 11.6 
T4 6 23.1 
Lymph node metastasis     
 Negative N0 11 42.3 
 Positive N1 7 28.0 
N2  8 30.7 
Distant metastasis    
  M0 26 100 
  M1 0  
TNM stage    
Early TNM stage 
I 6 23.0 
II 7 27.0 
 Advanced TNM 
stage 
III 2 7.7 













Table 1: OSCC, oral squamous cell carcinoma; the T and clinical stages were redis-
tributed in accordance with the guidelines of the NCI.
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Fig. 1: Levels of sE-cadherin as evaluated by ELISA, and the presence of mE-cadherin 
as determined by immunohistochemistry in OSCC. A) Concentration of sE-cadherin 
in the saliva from OSCC patients and controls (*p=0.031). Box: lower line - quartile 
Q1 (25%-quartile); middle line - median; and upper line - quartile Q3 (75%-quartile) 
(Wilcoxon-Mann-Whitney test, 95% C.I.). B) The expression of mE-cadherin in the 
tumor tissue was not predominantly high or low. The x-axis shows the score based on 
the HercepTest®. C) Low expression: 0, poorly differentiated carcinoma with absent 
mE-cadherin immunoreactivity (original magnification 20x); and 1+, well-differen-
tiated carcinoma with poor or absent mE-cadherin expression (original magnifica-
tion 20x). D) High expression: 2+, well-differentiated carcinoma with moderate and 
intense areas of mE-cadherin immunostaining (original magnification 20x); and 3+, 
well-differentiated carcinoma with evident, intense mE-cadherin immunostaining 
(original magnification 20x).
The presence of mE-cadherin was classified as either low 
or high based on the HercepTest®. No significant differ-
ences were found in mE-cadherin expression in tumors 
of different sizes (p=0.097); in contrast, statistically sig-
nificant differences were observed between positive and 
negative lymph nodes (p=0.015) as well as between early 
and advanced clinical stages (p=0.001) (Table 2). 
The degree of differentiation was not statistically signif-
icant (p=1.000) based on the presence of mE-cadherin.
-Expression of sE-cadherin and mE-cadherin
A comparison of the levels of sE-cadherin with the 
presence of mE-cadherin did not reveal statistically sig-
nificant differences. However, a trend toward an inverse 
relationship was observed: low levels of mE-cadherin 
were associated with high levels of sE-cadherin (me-
dian 6.46 ng/ml, minimum 2.67 ng/ml and maximum 
13.91 ng/ml), whereas high levels of mE-cadherin were 
associated with low levels of sE-cadherin (median 4.68 
ng/ml, minimum 1.48 ng/ml and maximum 9.63 ng/ml) 
(Fig. 2A).
This tendency was observed only in the most advanced 
stages. Advanced T stage cases showed an increase in 
the levels of sE-cadherin when the levels of mE-cadherin 
were low (median of 11.75, minimum of 3.75 and maxi-

















High Low p value 
Tumor Size     
Not advanced 11 6 0.097 
NS Advanced 2 7 
Lymph node metastasis     
Negative 9 2 0.015* 
Positive 4 11  
Distant metastasis     
Negative 14 12  
Positive 0 0  
TNM stage    
Early TNM stage 11 2 0.001** 
Advanced TNM stage 2 11  
Pathological grade    
Well 11 10  
Moderatly 2 2 1.000  
Poor 0 1           NS 
Table 2: Fisher’s Exact Test with 95% C.I. NS: no significance; *p<0.05; and ** 
p≤0.001.
mum of 14.16) compared with the levels of sE-cadherin 
when the levels of mE-cadherin were high (median of 
6.32, minimum of 1.87 and maximum of 9.21), but this 
difference was not statistically significant (Fig. 2B).
Nevertheless, positivity in regard to the invasion of 
lymphatic nodes and advanced clinical stage did show 
statistically significant differences. The levels of sE-
cadherin were higher when mE-cadherin was expressed 
at low levels (median of 6.63, minimum of 2.69 and 
maximum of 14.16) in positive nodes compared with the 
levels of sE-cadherin when mE-cadherin was robustly 
expressed (median of 1.83, minimum of 1.76 and maxi-
mum of 2.49) (p=0.014) (Fig. 2C). Similarly, the lev-
els of sE-cadherin when mE-cadherin expression was 
low (median of 6.63, minimum of 2.69 and maximum 
of 14.16) in advanced clinical stages were greater than 
the levels of sE-cadherin in the presence of high mE-
cadherin expression (median of 1.83, minimum of 1.76 
and maximum of 2.49) (p=0.037) (Fig. 2D).
Discussion
In this study, we found statistically significant dif-
ferences in the saliva sE-cadherin levels between the 
OSCC group and the group without OSCC. The results 
of this study are consistent with those of Al Kassam et 
al., who studied patients with head and neck cancer (21). 
That study showed statistically significant differences 
in the levels of sE-cadherin between the blood plasma 
of healthy individuals and that of cancer patients but not 
in terms of the TNM and clinical stages in a similar 
sample size. They also did not include comparisons re-
garding the tumor grade (differentiation).
An important difference between our study and other 
studies is the use of salivary fluid instead of blood plas-
ma. 
Despite the disadvantages we described concerning 
the methodology, we agree on the advantages in using 
saliva: collection of saliva is a non-invasive procedure, 
sample collectors do not need any special training, and 
the presence of normal materials (cells, DNA, RNA 
and proteins) and inhibitory substances is low (22). The 
detection of high levels of sE-cadherin in patients with 
oral cancer enables us to suggest the use of saliva as a 
tool for analysis when E-cadherin dysregulation needs 
to be determined. However, further studies are required 
to establish the features of sE-cadherin in the saliva and 
the relationship of sE-cadherin with the disease.
Since the degradation of the extracellular portion alone 
cannot lead to the total loss of E-cadherin protein, we 
also evaluated the expression of mE-cadherin (23).
The mE-cadherin expression results are consistent with 
those in many publications in which low expression is 
Med Oral Patol Oral Cir Bucal. 2017 Nov 1;22 (6):e694-701.                                                                                                            E-cadherin in oral squamous cell carcinoma
e700
Fig. 2: The levels of sE-cadherin as evaluated by ELISA and the expression of mE-cadherin as measured by immunohistochemistry were 
correlated with disease progression. A) Trend toward an inverse relationship: low expression of E-cadherin was associated with a high level of 
sE-cadherin, whereas high levels of E-cadherin were associated with low levels of sE-cadherin (p=0.178). B, C, D) This tendency was main-
tained in only the most advanced stages of the three clinical criteria. Advanced T stage cases showed an increase in the levels of sE-cadherin 
with low expression of mE-cadherin (p=0.245). In positive nodes, the levels of sE-cadherin were greater when mE-cadherin was expressed 
at low levels compared with the levels of sE-cadherin when mE-cadherin was expressed at high levels (*p=0.014). In cases at an advanced 
clinical stage, the levels of sE-cadherin when the expression level of mE-cadherin was low were greater than the levels of sE-cadherin when 
the expression level of mE-cadherin was high (*p=0.037). Box: lower line - quartile Q1 (25%-quartile); middle line - median; and upper line 
- quartile Q3 (75%-quartile) (Wilcoxon-Mann-Whitney test, 95% C.I.). Dotted line: median of sE-cadherin within the healthy control group.
statistically significantly correlated with node invasion 
and advanced TNM stage in OSCC (24,25). However, 
various studies have not found a statistically significant 
association between low or high membranous expres-
sion and the size of the tumor, which is in agreement 
with our results (7-9,26,27).
The main obstacle against the use of mE-cadherin ex-
pression as a trustworthy marker is the occurrence of 
false-positive detection, in which aggressive, invasive 
tumors express mE-cadherin (7-10). It has been sug-
gested that this is because many antibodies against E-
cadherin may only target the extracellular or intracel-
lular portions, and therefore, even with the loss of one 
portion of the protein, a positive immunoreaction may 
still be observed, which would affect the detection of 
malignancy.
These last observations also served to address the last 
objective of our study, which was to demonstrate new 
possible associations in OSCC via a comparison of the 
results of the immunohistochemical analysis to the lev-
els of sE-cadherin by ELISA to interpret the extracel-
lular events that accompany high or low mE-cadherin 
expression. The inverse relationship we observed was 
not statistically significant; however, when these values 
were grouped in accordance with node invasion and 
advanced TNM stage, this tendency became statisti-
cally significant. These results may be associated with 
the proteolytic events that occur in the tumor microen-
vironment. These proteolytic events enable neoplastic 
cells to migrate and invade other sites.
In contrast, a small number of OSCC cases exhibited 
high expression of mE-cadherin and higher median val-
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ues of sE-cadherin than the control group. This finding 
allows for the possibility to distinguish tumors by re-
vealing intracellular processes that mediate malignant 
pathways, independent of extracellular mE-cadherin 
proteolysis.
In addition, we need to consider the difference between 
statistical and biological significance, since other types 
of analyses were not included, e.g., gene expression 
analysis and/or expression analysis in the cytoplasmic 
region as well as the measurement of proteolytic en-
zymes that target E-cadherin. However, if our results 
are both statistically and biologically significant, a ther-
apeutic strategy could be designed to target extracel-
lular or intracellular proteolytic events.
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